Research Nester released a report titled “Alzheimer’s Treatment Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global Alzheimer’s treatment market in terms of market segmentation by drug class, by distribution channel, by product, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
According to the Alzheimer’s Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer’s disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050.
Alzheimer’s disease is a brain disorder characterized by the gradual degeneration of the brain tissue, which eventually results in temporary or permanent loss of memory. The Alzheimer’s treatment market is anticipated to grow at a CAGR of 7.44% over the forecast period, i.e., 2020-2027. The market is further projected to attain a market value of USD 2,008.17 million by the end of 2027. The market is segmented by drug class, by distribution channel, by product, by end user and by region. The segment for drug class is further segmented into standalone drugs and combination drugs, out of which, the standalone segment is sub-segmented into cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) antagonist. The segment for standalone drugs is predicted to lead the market with highest market share, while the segment for combination drugs is anticipated to grow at the highest CAGR of 8.69% over the forecast period.
On the basis of region, the Alzheimer’s treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America holds the major share of Alzheimer’s treatment market on account of increasing incidences of the disease. With the presence of key players in the region, the North America Alzheimer’s treatment market is further predicted to expand rapidly on the back of increasing technological advancements in the field. The market in Europe is predicted to grow on account of rising geriatric population in the region.
Rising Cases of Alzheimer’s Disease to Drive the Market Growth
Alzheimer’s disease is considered as the most common form of dementia among the elderly population. The rising cases of Alzheimer’s disease have created a huge demand for effective treatment for the disease. This is projected to contribute significantly to the growth of the market in the near future. However, the high standards required for the approval of any drug or device for the treatment of Alzheimer’s disease is estimated to become a major barrier for the market growth.
This report also provides the existing competitive scenario of some of the key players of the global Alzheimer’s treatment market which includes company profiling of NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. and Neuronix. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Alzheimer’s treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.